021. 007/CP46 ;HEBON thanks the registration teams of the  Comprehensive Cancer Centre Netherlands and Comprehensive Centre South  (together the  Netherlands Cancer Registry)  and  PALGA (Dutch Pathology Registry)  for part of the data collection; the  High Risk Breast Cancer Program (HRBCP)  is supported by the  Hong Kong Hereditary Breast Cancer Family Registry  and the  Dr Ellen Li Charitable Foundation ,  Hong Kong ; the  Hungarian Breast and Ovarian Cancer Study (HUNBOCS)  was supported by  Hungarian Research and Technological Innovation Fund (KTIA) / Hungarian Scientific Research Fund (Országos Tudományos Kutatási Alapprogramok (OTKA) ) research grants  KTIA-OTKA CK-80745  and  KTIA-OTKA K-112228 ;  Institut Català d'Oncologia (ICO) : contract grant sponsor: Asociación Española Contra el Cáncer;  Spanish Health Research Foundation ;  Ramón Areces Foundation ;  Instituto de Salud Carlos III (ISCIII) ;  Catalan Health Institute ; and  Autonomous Government of Catalonia ; contract grant numbers ISCIIIRETIC  RD06/0020/1051 ,  PI09/02483 ,  PI10/01422 ,  PI10/00748 ,  PI13/00285 ,  PI13/00189 2009SGR290  and  PI13/00189 2009SGR283 ; the  International Hereditary Cancer Center  ( Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland ) was supported by grant  PBZ_KBN_122/P05/2004 ; Landspitali -The  National University Hospital of Iceland  was supported by the  Icelandic Association "Walking for Breast Cancer Research " and by the  Landspitali University Hospital Research Fund ; the  Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT)  was supported by the  Canadian Institutes of Health Research (CIHR)  for the " CIHR Team in Familial Risks of Breast Cancer" program ,  Canadian Breast Cancer Research Alliance  grant  019511  and  Ministry of Economic Development, Innovation and Export Trade  grant  PSR-SIIRI-701 ; the  Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOVHBOCS)  is supported by the  Ministero della Salute  and a "5 × 1, 000 "  Istituto Oncologico Veneto  grant; the  Portuguese Oncology Institute-Porto Breast Cancer Study  (IPOBCS) was supported in part by  Liga Portuguesa Contra o Cancro ; kConFab is supported by a grant from the  National Breast Cancer Foundation  and previously by the  National Health and Medical Research Council (NHMRC) , the  Queensland Cancer Fund , the  Cancer Councils of New South Wales, Victoria , Tasmania and  South Australia , and the  Cancer Foundation of Western Australia ; the  Mayo Clinic  is supported by  National Institutes of Health (NIH)  grants  CA 116167 ,  CA 128978  and  CA 176785  through the  National Cancer Institute (NCI) , an  NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer  ( CA116201 ), a  US Department of Defense Ovarian Cancer Idea award  ( W81XWH-10-1-0341 ), a grant from the  Breast Cancer Research Foundation , a generous gift from the  David F and Margaret T Grohne Family Foundation  and the  Ting Tsung and Wei Fong Chao Foundation ;  McGill University Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade ;  Modifier Study of Quantitative Effects on Disease (ModSQuaD)  was supported by the  Ministry of Health of the Czech Republic to Masaryk Memorial Cancer Institute (MH CZ -DRO)  ( MMCI 00209805 ) and by the  European Regional Development Fund  and the  State Budget of the Czech Republic (RECAMO ,  CZ.